EA 2216, Université de Bretagne, Brest, France.
J Hematol Oncol. 2010 Dec 7;3:49. doi: 10.1186/1756-8722-3-49.
We previously reported that allanxanthone C and macluraxanthone, two xanthones purified from Guttiferae trees, display in vitro antiproliferative and proapoptotic activities in leukemic cells from chronic lymphocytic leukemia (CLL) and leukemia B cell lines.
Here, we investigated the in vivo therapeutic effects of the two xanthones in a xenograft murine model of human CLL, developed by engrafting CD5-transfected chronic leukemia B cells into SCID mice. Treatment of the animals with five daily injections of either allanxanthone C or macluraxanthone resulted in a significant prolongation of their survival as compared to control animals injected with the solvent alone (p = 0.0006 and p = 0.0141, respectively). The same treatment of mice which were not xenografted induced no mortality.
These data show for the first time the in vivo antileukemic activities of two plant-derived xanthones, and confirm their potential interest for CLL therapy.
我们之前报道过，从藤黄科树木中分离得到的两种紫檀烷酮，即 Allanxanthone C 和 Macluraxanthone，在慢性淋巴细胞白血病（CLL）和白血病 B 细胞系的白血病细胞中具有体外抗增殖和促凋亡活性。
在这里，我们通过将转染 CD5 的慢性白血病 B 细胞注入 SCID 小鼠，建立了人 CLL 的异种移植小鼠模型，研究了这两种紫檀烷酮的体内治疗效果。与单独注射溶剂的对照组动物相比，用 Allanxanthone C 或 Macluraxanthone 连续五天注射治疗的动物的存活时间显著延长（p = 0.0006 和 p = 0.0141）。未进行异种移植的小鼠接受相同的治疗并未诱导任何死亡率。
这些数据首次表明两种植物来源的紫檀烷酮具有体内抗白血病活性，并证实它们对 CLL 治疗具有潜在的意义。
